WhaleCreep

Avidity Partners Management LP 13F holdings, Q2 2024

Hedge fundSEC filingsCompare with another fundHoldings as of 2024-06-30, filed 2024-08-14

Avidity Partners Management LP disclosed 85 US equity positions worth $2.4bn in its Q2 2024 13F filing. Its largest position is ISRG at 4.6% of the reported book, followed by BSX and NTRA. Versus Q1 2024 it opened 18 new positions, added to 27, reduced 25 and exited 20.

$2.4bn
Reported equity book
Sum of the long US equity positions in the filing, at the values filed. Options are excluded.
85
Positions
Distinct securities in the equity book with a reported value above zero. Options are excluded.
4.6%
Largest position
The largest single position as a share of the reported equity book.
32.9%
Top 10 weight
The ten largest positions together, as a share of the reported equity book.
49
Effective positions
1 / HHI of portfolio weights: the number of equal-weight positions the book behaves like.
27
Quarters on file since Q4 2019
Quarters for which this manager's 13F holdings are on record.

Holdings

Against Q1 2024: 18 new, 27 added, 25 reduced, 20 exited

50 of 85
ISRG INTUITIVE SURGICAL INCHealthcare4.6%$109m245,000+8.4%added
BSX BOSTON SCIENTIFIC CORPHealthcare3.8%$90.1m1.17m−40%reduced
NTRA NATERA INCHealthcare3.5%$83.0m766,500−4.6%reduced
ARVN ARVINAS INCHealthcare3.4%$79.5m2.99m+0.1%held
ACHC ACADIA HEALTHCARE COMPANY INHealthcare3.2%$75.6m1.12m+11%added
DNTH DIANTHUS THERAPEUTICS INCHealthcare3.2%$75.5m2.92m+7.3%added
SNDX SYNDAX PHARMACEUTICALS INCHealthcare2.9%$68.5m3.33m+38%added
NBIX NEUROCRINE BIOSCIENCES INCHealthcare2.9%$67.6m491,000−8.5%reduced
AVTR AVANTOR INCHealthcare2.8%$65.4m3.09m+15%added
CI THE CIGNA GROUPHealthcare2.6%$61.0m184,5000.0%held
JAZZ JAZZ PHARMACEUTICALS PLCHealthcare2.5%$58.1m544,500−6.8%reduced
ALNY ALNYLAM PHARMACEUTICALS INCHealthcare2.3%$53.9m222,000−8.6%reduced
REGN REGENERON PHARMACEUTICALSHealthcare2.1%$50.4m48,000−29%reduced
ILMN ILLUMINA INCHealthcare2.1%$49.9m478,000+3.0%added
THC TENET HEALTHCARE CORPHealthcare2.1%$49.5m372,000−38%reduced
ABBV ABBVIE INCHealthcare2.0%$47.6m277,800+22%added
TMO THERMO FISHER SCIENTIFIC INCHealthcare1.9%$44.2m80,000+119%added
GPCR STRUCTURE THERAPEUTICS INCHealthcare1.8%$42.2m1.07m+24%added
2655787D BLUEPRINT MEDICINES CORP–1.8%$41.3m383,000−10%reduced
CGON CG ONCOLOGY INCHealthcare1.7%$40.9m1.30m−11%reduced
MRK MERCK & CO. INCHealthcare1.7%$40.2m325,000−35%reduced
RARE ULTRAGENYX PHARMACEUTICAL INHealthcare1.7%$39.5m960,000+2.8%added
IDYA IDEAYA BIOSCIENCES INCHealthcare1.7%$39.2m1.12m+40%added
DHR DANAHER CORP DELHealthcare1.6%$37.5m150,000+4.3%added
JANX JANUX THERAPEUTICS INCHealthcare1.5%$35.2m840,219+119%added
UTHR UNITED THERAPEUTICS CORP DELHealthcare1.5%$35.0m110,000−49%reduced
INCY INCYTE CORPHealthcare1.4%$32.1m529,000–new
SGRY SURGERY PARTNERS INCHealthcare1.3%$31.1m1.31m−9.6%reduced
CATX PERSPECTIVE THERAPEUTICS INC–1.3%$30.3m3.04m–new
AXSM AXSOME THERAPEUTICS INC.Healthcare1.3%$30.3m376,000−13%reduced
XENE XENON PHARMACEUTICALS INCHealthcare1.2%$29.4m754,000+6.2%added
DXCM DEXCOM INCHealthcare1.2%$29.4m259,000+46%added
RVMD REVOLUTION MEDICINES INCHealthcare1.2%$29.3m755,000+19%added
INSM INSMED INCHealthcare1.2%$28.8m430,000–new
ITCIEUR INTRA-CELLULAR THERAPIES INC–1.2%$27.4m400,000−33%reduced
CGEM CULLINAN THERAPEUTICS INCHealthcare1.2%$27.2m1.56m–new
GKOS GLAUKOS CORPHealthcare1.1%$26.5m224,0000.0%held
NGNE NEUROGENE INCHealthcare1.1%$26.5m727,537+56%added
ARGX ARGENX SEHealthcare1.1%$26.0m60,500–new
MIRM MIRUM PHARMACEUTICALS INCHealthcare1.1%$25.0m731,104−36%reduced
ESTA ESTABLISHMENT LABS HLDGS INCHealthcare1.0%$24.1m531,000+136%added
IMVT IMMUNOVANT INCHealthcare1.0%$24.0m908,000+80%added
RCKT ROCKET PHARMACEUTICALS INCHealthcare1.0%$23.7m1.10m+7.3%added
LNTH LANTHEUS HLDGS INCHealthcare1.0%$23.3m290,000−40%reduced
PCVX VAXCYTE INCHealthcare0.9%$21.4m284,0000.0%held
APGE APOGEE THERAPEUTICS INCHealthcare0.8%$19.2m487,000+27%added
JSPR JASPER THERAPEUTICS INC–0.8%$17.8m782,000+2.9%added
NMRA NEUMORA THERAPEUTICS INC.Healthcare0.8%$17.7m1.80m0.0%held
LEGN LEGEND BIOTECH CORPHealthcare0.7%$17.6m398,000−40%reduced
GILD GILEAD SCIENCES INCHealthcare0.7%$17.5m255,000–new

Exited since Q1 2024

20 rows
FUSION PHARMACEUTICALS INC no ticker4.9%$139m
ALGN ALIGN TECHNOLOGY INC2.2%$62.0m
LLY ELI LILLY & CO1.9%$54.5m
NVLSEUR ALPINE IMMUNE SCIENCES INC1.7%$46.6m
CVS CVS HEALTH CORP1.5%$43.5m
CRBU CARIBOU BIOSCIENCES INC1.1%$29.7m
MCK MCKESSON CORP0.6%$17.9m
VERA VERA THERAPEUTICS INC0.6%$16.5m
CATBUSD ASTRIA THERAPEUTICS INC0.5%$13.8m
CYTK CYTOKINETICS INC0.4%$11.6m
RDNT RADNET INC0.4%$11.6m
ACAD ACADIA PHARMACEUTICALS INC0.4%$10.9m
IPSC CENTURY THERAPEUTICS INC0.2%$5.1m
KYTX KYVERNA THERAPEUTICS INC0.2%$5.0m
EBS EMERGENT BIOSOLUTIONS INC0.2%$4.8m
ANTX AN2 THERAPEUTICS INC0.1%$3.7m
GINKGO BIOWORKS HOLDINGS INC no ticker0.1%$3.5m
XFOR X4 PHARMACEUTICALS INC0.1%$3.4m
PACB PACIFIC BIOSCIENCES CALIF IN0.09%$2.5m
KOD KODIAK SCIENCES INC0.06%$1.6m

Sector mix

  • Healthcare91.8%
  • Unclassified7.4%
  • Basic Materials0.6%
  • Technology0.2%

Book over time

Every quarter on file (27)
QuarterPositionsEquity book
Q2 202645$624m
Q1 202645$494m
Q4 202539$347m
Q3 202543$439m
Q2 202555$499m
Q1 202563$485m
Q4 202461$1.0bn
Q3 202481$2.0bn
Q2 202485$2.4bn
Q1 202487$2.8bn
Q4 202372$2.6bn
Q3 202383$2.5bn
Q2 202393$2.9bn
Q1 202383$3.0bn
Q4 202284$4.3bn
Q3 202296$4.6bn
Q2 202282$4.4bn
Q1 202291$4.5bn
Q4 202197$4.7bn
Q3 2021103$3.9bn
Q2 2021112$3.7bn
Q1 202193$3.6bn
Q4 202094$3.0bn
Q3 202066$1.9bn
Q2 202057$1.6bn
Q1 202049$698m
Q4 201933$159m

Where Avidity Partners Management LP was early

46 rows
BTAI BIOXCEL THERAPEUTICS INCQ1 20202 of 560.7%1.3%4Exited by Q1 2021+3.4%
ALEC ALECTOR INCQ1 20205 of 872.5%2.5%2Exited by Q3 2020+1.3%
VSTM VERASTEM INCQ1 20205 of 1001.1%1.1%2Exited by Q3 2020−35%
AXSM AXSOME THERAPEUTICS INCQ1 20208 of 1411.7%2.1%17Exited by Q3 2025+77%
IDYA IDEAYA BIOSCIENCES INCQ2 20201 of 1081.2%2.9%19Exited by Q2 2025+15%
ZNTL ZENTALIS PHARMACEUTICALS INCQ2 20203 of 872.1%4.8%14Exited by Q4 2023−58%
VIR VIR BIOTECHNOLOGY INCQ2 20204 of 1141.6%1.7%11Held at last filing, Q2 2026−75%
LEGN LEGEND BIOTECH CORPQ2 20205 of 1210.3%2.6%14Held at last filing, Q2 2026−32%
NTLA INTELLIA THERAPEUTICS INCQ2 20206 of 1290.6%1.7%16Held at last filing, Q2 2026−20%
SNDX SYNDAX PHARMACEUTICALS INCQ2 20206 of 1271.5%3.5%21Exited by Q3 2025−37%
ARVN ARVINAS INCQ2 20208 of 1212.3%5.1%22Exited by Q4 2025−75%
AVTR AVANTOR INCQ2 20209 of 1841.8%6.2%17Exited by Q2 2025−4.7%
NBP I MABQ3 20202 of 663.4%3.4%5Exited by Q4 2021+54%
NTRA NATERA INCQ3 202010 of 1672.0%6.8%23Exited by Q2 2026+177%
MRVI MARAVAI LIFESCIENCES HLDGS IQ4 20201 of 1163.2%3.3%3Exited by Q3 2021+49%
ATEC ALPHATEC HLDGS INCQ4 20203 of 1020.9%1.1%10Exited by Q4 2023−11%
ORGO ORGANOGENESIS HLDGS INCQ4 20203 of 671.4%1.4%2Exited by Q2 2021+142%
SHC SOTERA HEALTH COQ4 20203 of 1320.6%1.6%5Exited by Q1 2022−14%
STTK SHATTUCK LABS INCQ4 20203 of 651.7%1.7%5Exited by Q1 2022−84%
SGRY SURGERY PARTNERS INCQ4 20205 of 1320.5%3.8%11Exited by Q1 2025−27%
IMCR IMMUNOCORE HLDGS PLCQ1 20212 of 970.7%2.1%15Exited by Q4 2024−27%
NUVB NUVATION BIO INCQ1 20213 of 972.2%2.2%6Exited by Q3 2022−69%
ACET ADICET BIO INCQ1 20217 of 720.8%1.4%5Exited by Q2 2022+53%
CGEM CULLINAN THERAPEUTICS INCQ1 20219 of 920.8%1.2%3Exited by Q4 2024−60%
BBIO BRIDGEBIO PHARMA INCQ1 202113 of 1741.4%1.4%6Held at last filing, Q2 2026+21%
CMPS COMPASS PATHWAYS PLCQ2 20214 of 1071.0%1.0%2Exited by Q4 2021−22%
DOCS DOXIMITY INCQ2 20218 of 1330.2%1.5%3Exited by Q3 2025+5.4%
STVN STEVANATO GROUP S P AQ3 20212 of 621.6%1.6%2Exited by Q1 2022−11%
CRBU CARIBOU BIOSCIENCES INCQ3 20214 of 731.5%1.5%11Exited by Q2 2024−78%
ALT ALTIMMUNE INCQ3 20218 of 1040.6%1.5%10Exited by Q3 2025−66%
KYMR KYMERA THERAPEUTICS INCQ3 20219 of 980.8%2.0%4Exited by Q1 2025−32%
RARE ULTRAGENYX PHARMACEUTICAL INQ3 20219 of 1511.0%3.2%16Exited by Q3 2025−60%
RVMD REVOLUTION MEDICINES INCQ2 20228 of 1640.6%1.9%14Exited by Q2 2026+399%
PLRX PLIANT THERAPEUTICS INCQ3 202210 of 1030.9%2.4%4Exited by Q3 2023−13%
TMDX TRANSMEDICS GROUP INCQ3 202210 of 1080.3%1.2%3Exited by Q1 2025+49%
PCVX VAXCYTE INCQ3 202213 of 1210.3%1.8%9Exited by Q2 2025+57%
BHVN BIOHAVEN LTDQ4 20229 of 1260.5%1.9%10Exited by Q2 2025+73%
ICLR ICON PLCQ4 202215 of 1611.0%1.7%4Exited by Q2 2026−43%
GPCR STRUCTURE THERAPEUTICS INCQ2 20239 of 1140.06%1.8%8Held at last filing, Q2 2026+29%
MLTX MOONLAKE IMMUNOTHERAPEUTICSQ2 202311 of 1210.7%1.8%4Exited by Q2 2026−63%
NMRA NEUMORA THERAPEUTICS INC.Q3 20233 of 751.0%1.3%5Exited by Q4 2024−6.4%
DNTH DIANTHUS THERAPEUTICS INCQ3 20235 of 970.7%35.8%12Held at last filing, Q2 2026+613%
CGON CG ONCOLOGY INCQ1 20242 of 882.3%17.7%10Held at last filing, Q2 2026+62%
JANX JANUX THERAPEUTICS INCQ1 20249 of 1090.5%4.0%5Exited by Q2 2025−28%
ORKA ORUKA THERAPEUTICS INCQ3 20247 of 831.0%11.6%8Held at last filing, Q2 2026+288%
JBIO JADE BIOSCIENCES INCQ2 20252 of 522.3%6.2%5Held at last filing, Q2 2026+122%

Concentration and tenure

6.2%
Median largest position, all quarters
The largest single position as a share of the reported equity book.
39.7%
Median top 10 weight, all quarters
The ten largest positions together, as a share of the reported equity book.
Concentrated
Style, by median largest position
2
Median completed holding, quarters